-
Global travel continues to increase, with over 800 million tourist arrivals recorded worldwide in 2005. Increasing numbers of international travelers are returning with dengue fever.
-
The May 23/30, 2007, issue of JAMA was devoted to malaria and contained an informative selection of papers.
-
-
Estrogen for Younger Postmenopausal Women; Warfarin Better for Atrial
Fibrillation Patients; FDA Actions
-
In an effort to ensure quality cardiac ultrasound imaging and to avoid unnecessary use of the technology, the American Society of Echocardiography (ASE; Raleigh, North Carolina) and the American College of Cardiology Foundation (ACCF; Washington), in partnership with five other groups, released Appropriateness Criteria for two of the most commonly used cardiac ultrasound techniques transthoracic (TTE) and transesophageal (TEE) echocardiography just in time for the 18th annual Scientific Sessions of ASE in Seattle in June.
-
DENVER Around 95% of those struck by sudden cardiac arrest (SCA) die. A new group, the Sudden Cardiac Arrest Coalition, would like to reverse this to 90% saved with the use of defibrillation very quickly after the heart stops because of an electrical short in the hearts system.
-
BARCELONA Valve replacement is the new frontier for minimally invasive coronary interventions, and three companies have emerged as front-runners in the race to stake out a claim of a market that senior executives from each company described, in a word, as "huge."
-
The medical device market is famously litigious, but legal disputes appeared to come even faster and more furiously in the cardiovascular sector over the past month, all likely to either maintain or shift market positions in some key areas of the sector.
-
St. Jude Medical (St. Paul, Minnesota) in early July reported U.S. and European regulatory approvals to expand the capabilities of its Frontier II cardiac resynchronization therapy pacemaker (CRT-P) to include QuickOpt Timing Cycle Optimization, giving physicians a new option to manage therapy for patients based on their individual needs.
-
Two years after a 70-year-old retired construction worker became the first enrollee in the Fix Heart Failure 5 (FIX-HF-5) study by being implanted with the Optimizer III device from Impulse Dynamics (Orangeburg, New York), the company last month reported completion of patient enrollment in the trial. The first patient was implanted with the device at St. Josephs Hospital (Atlanta) in April 2005.
